We are proud of being a Silver Sponsor of the ESGCT 2023, the European Society of Gene and Cell Therapy, Annual Congress.
Each year, the European Society of Gene and Cell Therapy meets over 100 world-leading experts presenting their latest research at this anual congress featuring the hot topics and ground-breaking research in gene and cell therapy.
We are excited of being exhibiting at booth number 63. An amazing opportunity to conect with you to tackle the most pressing issues in rAAV manufacturing and learn from this week exploring the latest challenges, developments, and innovations in #genetherapy.
When: Brussels, Belgium
Where: October 24 – 27
Meet us at ESGCT 2023: Contact now to schedule a meeting.
neDNA™: first option for critical starting material for rAAV manufacturing
neDNA™, TAAV-manufactured enzymatic DNA, is an alternative to plasmid for rAAV manufacturing. It is designed to transform and accelerate the traditional Gene Therapy Development Timelines.
TAAV’s enzymatic DNA is a synthetic, linear, double-stranded, closed-ended molecule which we aim to be the new standard for transfection-based rAAV generation.
neDNA™ intends to be safer producing higher and faster yields at lower costs than plasmid.
✔ Likely Safer ✔ Higher Yield ✔ Scalable ✔ Faster to Manufacture ✔ Robust
See you in Brussels!
